{
    "nct_id": "NCT06533059",
    "official_title": "AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients With Advanced Solid Tumors With AKT1 E17K Mutation",
    "inclusion_criteria": "* Histologically confirmed diagnosis of a solid tumor malignancy harboring AKT1 E17K mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic test.\n* Unresectable or metastatic disease\n* Progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapy, if applicable) appropriate to tumor type and stage\n* Evaluable or measurable disease per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with PI3K and/or mTOR inhibitors\n* Patients known to have KRAS, NRAS, HRAS, or BRAF genomic alterations in their tumor\n* Known condition that prohibits ability to swallow or absorb an oral medication\n\nOther inclusion/exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}